Matsuki et al., page 1

Selective loss of GABA_B receptors in orexin/hypocretin-producing neurons results in disrupted sleep/wakefulness architecture Taizo Matsuki^{1,2}, Mika Nomiyama¹, Hitomi Takahira², Noriko Hirashima², Thomas S. Kilduff³, Satoshi

Kunita⁴, Satoru Takahashi^{4,5}, Ken-ichi Yagami⁴, Bernhard Bettler⁶, Masashi Yanagisawa^{1,7}, Takeshi Sakurai^{1,2,*}

¹Yanagisawa Orphan Receptor Project, Exploratory Research for Advanced Technology (ERATO), Japan Science and Technology Agency, Tokyo 135-0064, Japan; ²Department of Pharmacology, Institute of Basic Medical Sciences, University of Tsukuba, Ibaraki 305-8575, Japan; ³Neurobiology Laboratory, Biosciences Division, SRI International, 333 Ravenswood Avenue, Menlo Park, CA 94025, USA; ⁴Laboratory Animal Resource Center, and ⁵Department of Anatomy and Embryology, Institute of Basic Medical Sciences, University of Tsukuba, Ibaraki 305-8575, Japan; ⁶Department of Biomedicine, Institute of Physiology, Pharmazentrum, University of Basel, CH-4056 Basel, Switzerland; ⁷Howard Hughes Medical Institute and Department of Molecular Genetics, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas 75390

Address for correspondence: Dr. Takeshi Sakurai, Department of Pharmacology, Medical Sciences, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Ibaraki 305-8575, Japan; Phone & Fax: +81-29-853-3276, E-mail: stakeshi@md.tsukuba.ac.jp

Number of Figures and Tables: 6 figures and 1 table

Number of Pages: 40 pages

Keywords: orexin, sleep, interneuron, IPSC, GABA, GABA_B receptor

Acknowledgements

This study was supported in part by a grant-in-aid for scientific research and the 21st Century COE Program from the Ministry of Education, Science, and Culture of Japan, Health and Labour Sciences Research Grants for Research on Measures for Intractable Diseases, Research Fellowships of the Japan Society for the Promotion of Science for Young Scientists, Mitsui Life Social Welfare Foundation and ERATO from the Japan Science and Technology Agency, NIH (RO1MH61755, T. Kilduff), and the Swiss Science Foundation (3100-067100.01, B. Bettler).

Author Contributions

T.M. and T.S. conducted the experiments and performed the analyses, and also participated in the design of the experiments. All authors contributed to discussion of the data and writing of the paper.

Competing Interests Statement

The authors declare that they have no competing financial interests.

Abstract

We generated mice with a selective loss of GABA_B receptors in orexin neurons. Orexin neurons in

these GABA_{B1}-/-(orexin) mice showed reduced responsiveness to GABA_A receptor agonists due to a

compensatory increase in GABA_A receptor-mediated inhibition. This increased GABA_A

receptor-mediated inhibition of orexin neurons is due to orexin-1 receptor-mediated activation of

local GABAergic interneurons. Surprisingly, orexin neurons were also less responsive to glutamate,

apparently because the augmented GABA_A receptor-mediated inhibition increases the membrane

conductance and shunts excitatory currents. These observations indicate that absence of GABA_B

receptors decreases the sensitivity of orexin neurons to both excitatory and inhibitory inputs.

GABA_{B1}-/-(orexin) mice exhibited severe fragmentation of sleep/wake states during both the light and

dark periods without affecting total sleep time or inducing cataplexy, indicating that GABA_B receptors

are crucial regulators of orexin neurons and that "fine tuning" of orexin neurons by inhibitory and

excitatory inputs is important for the stability of sleep/waking states.

Orexin A and orexin B, also known as hypocretin-1 and hypocretin-2, are critical regulators of

sleep/wakefulness states¹. Orexin neurons are localized exclusively in the lateral hypothalamic area

(LHA) and send excitatory projections to the waking-active monoaminergic neurons in the

hypothalamus and brainstem regions¹. The importance of orexins in the maintenance of

consolidated sleep/wakefulness states is demonstrated by the fact that the sleep disorder

narcolepsy is caused by orexin deficiency in human and animals²⁻⁵. Investigations of the efferent

and afferent systems of orexin neurons and phenotypic characterization of genetically-modified mice

have suggested additional functions for the orexins in the coordination of emotions, energy

homeostasis, reward systems, drug addiction, and arousal¹.

The regulatory mechanisms of orexin neurons are important for understanding the

physiological basis of sleep/wake control. In vitro studies showed that the activity of orexin neurons

is influenced by several neuropeptides and neurotransmitters¹. Recent studies showed that orexin

neurons receive innervation from several brain regions, including the limbic system (amygdala, bed

nucleus of the stria terminalis, and septal regions), preoptic area, and monoaminergic neurons^{1,6}.

Orexin neurons also receive glutamatergic and GABAergic innervation from local interneurons^{1,7}. *In vitro* electrophysiological studies showed that both GABA_A and GABA_B agonists inhibit the activity of orexin neurons⁷⁻⁹, but the physiological relevance of such regulation is unknown.

GABA_B receptors (GABA_BRs) are heterodimers composed of GABA_{B1} and GABA_{B2} subunits, both of which are required for normal receptor function^{10,11}. GABA_B receptors are coupled to G-proteins and modulate synaptic transmission by activating postsynaptic inwardly rectifying Kir3 K⁺ channels (GIRK channels) and by controlling neurotransmitter release through coupling to Ca²⁺ channels^{12,13}. Dysfunction of GABA_B-mediated synaptic transmission in the central nervous system occurs in several neurological disorders¹³⁻¹⁵. Among sleep disorders, the partial GABA_BR agonist gamma-hydroxybutyrate (GHB)¹⁶ is used to treat both the excessive sleepiness and cataplexy symptoms of human narcolepsy. GABA_BR activation inhibits presynaptic release of both glutamate and GABA onto orexin neurons⁹ and both pre- and postsynaptic GABA_BRs modulate the activity of orexin neurons⁹. In the present study, we engineered mice with a selective deletion of the GABA_{B1} gene in orexin neurons (orexin neuron-restricted knockout mice; GABA_{B1}-/-(orexin) mice) to study the consequences of the absence of GABA_BRs on orexin neuron function at the cellular and behavioral levels.

Results

Mice Selectively Lacking Functional GABA_B Receptors in Orexin Neurons

The GABA_{B1} subunit is essential for the assembly of functional GABA_B receptors and mice lacking

the GABA_{B1} subunit show a complete absence of GABA_B responses¹⁷. To obtain mice with a deletion

of the GABA_{B1} subunit gene restricted to orexin-producing neurons (GABA_{B1}-^{-/-(orexin)} mice), orexin/Cre

transgenic mice (see supplementary information) were mated with homozygous floxed GABA_{B1} mice

possessing exon 7 and 8 of the GABA_{B1} allele flanked by lox-P sites¹⁸. Double immunofluorescence

studies in wild-type control mice showed that many neurons in the LHA had GABA_{B1}-ir in their soma

and dendrites (Figure 1). Among these, many neurons in the LHA were positive for both orexin-ir

and GABA_{B1}-ir (Figure 1). In contrast, neurons positive for both GABA_{B1}-ir and orexin-ir were rarely

detectable in the brain of GABA_{B1}-'-(orexin) mice, although there were many GABA_{B1}-ir-positive neurons

in the LHA that were negative for orexin (Figure 1). We found that less than 10% of orexin neurons in

GABA_{B1}-/-(orexin) mice were double-labelled for orexin and GABA_{B1}-ir. This may be due to incomplete

penetrance of Cre expression in orexin/Cre transgenic mice and/or incomplete deletion of loxP sites

in GABA_{B1}-/-(orexin) mice. These observations indicate that in GABA_{B1}-/-(orexin) mice, more than 90% of

orexin neurons lack expression of GABA_B receptors. Gross anatomical and histological studies

failed to detect any structural abnormalities in the brain of GABA_{B1}-/-(orexin) mice. Specifically, the

number of orexin neurons in the LHA remained normal; the number of immunoreactive cells (located

from 0.76 mm to 2.52 mm posterior to bregma) were 3420±124 and 3560±108 for control littermates

and $GABA_{B1}^{-/-(orexin)}$ mice, respectively (n=5).

 $GABA_{B1}^{--(\text{orexin})}$ mice showed normal development of body weight; body weights at 22 weeks of age were 35.9 ± 2.9 , 34.9 ± 2.5 , and 34.8 ± 1.8 g for $GABA_{B1}^{\text{flox/+}}$, orexin/Cre Tg mice (n=9),

GABA_{B1}^{flox/flox} (orexin/Cre negative) mice (n=6), and GABA_{B1}^{-/-(orexin)} mice (n=6), respectively (p=0.35,

ANOVA with Bonferroni correction). Expression levels of hypothalamic neuropeptides, including

orexin, neuropeptide Y, proopiomelanocortin, and melanin concentrating hormone, did not differ

between GABA_{B1}-/-(orexin) and control mice, as determined by quantitative RT-PCR using Taqman

probes or immunohistochemical analysis (data not shown). In contrast to conventional GABAB1 KO

mice that exhibit contextual hyperactivity,¹⁷ locomotor activity of GABA_{B1}-/-(orexin) mice across the 24 hr

period was not altered (data not shown).

Electrophysiological Characteristics of Orexin Neurons Lacking GABA_B Receptors

The electrophysiological properties of orexin neurons were examined in GABA_{B1}^{-/-(orexin)} mice by

patch-clamp recordings using brain slice preparations (Figure 2). Bath application of GABA (0.6 mM)

or muscimol (30 µM) produced hyperpolarization of orexin neurons in both control (GABA_{B1}^{flox/+},

orexin/Cre Tg or GABA_{B1}^{flox/flox}, orexin/Cre negative) and GABA_{B1}^{-/-(orexin)} mice (Figure 2a, b). These

GABA- and muscimol-induced effects rapidly reversed upon removal of these reagents from the

external solution (Figure 2a, b). To specifically examine GABA_B receptor-mediated effects on

neuronal activity, we applied the GABA_B agonist baclofen. Bath application of baclofen (100 μ M)

hyperpolarized all orexin neurons tested in control slices (n=6) (Figure 2a). As expected from the

histological data in Figure 1, baclofen failed to induce hyperpolarization in 10 out of 12 orexin

neurons tested in slices from six GABA_{B1}-^{--(orexin)} mice (Figure 2b). Application of 5-hydroxytryptamine

(5-HT) induced strong hyperpolarization of orexin neurons regardless of genotype, suggesting that

downstream signaling systems of Gi/o-coupled receptors, including the activation of Kir3 channels,

remain intact in $GABA_{B1}^{--(orexin)}$ mice (Figure 2a, b).

In current-clamp mode, orexin neurons lacking GABA_B receptors showed a resting membrane potential and firing frequency similar to that of orexin neurons in control littermates (GABA_{B1}-/-(orexin): -59.2±5.8 mV, 5.1±2.6 Hz, n=12; control: -55.0±2.9 mV, 4.0±0.7 Hz, n=12), indicating that GABA_B receptor-deficient orexin neurons have a basal activity comparable to that of control neurons, despite the absence of a major inhibitory receptor. However, the frequency of fast spontaneous inhibitory postsynaptic currents (sIPSCs) of orexin neurons in GABA_{B1}-/-(orexin) slices was significantly increased compared to that in slices from control littermates (GABA_{B1}-'-(orexin): 2.65±0.32 Hz, n=9; control: 1.59±0.12 Hz, n=13; p=0.011) (Figure 3a, b). Bath application of baclofen (100 μ M) decreased the frequency of sIPSCs to 3.4% and 23% of control values (in the absence of baclofen) in control littermates and GABA_{B1}-/-(orexin) mice, respectively (Figure 3a, b). This suggests that sIPSCs on orexin neurons are elicited by GABA release from GABAergic terminals having presynaptic GABA_B receptors (Figure 3a, b). Next, we examined the effects of the GABA_A

and GABA_B receptor antagonists bicuculline (BIC) and CGP54626, respectively, on the activity of

orexin neurons. Consistent with our previous study⁹, orexin neurons in wild-type control slices did

not respond to applications of the antagonists BIC (25 μ M) or CGP54626 (12 μ M) (Figure 3c and

data not shown). In contrast, orexin neurons in slices from GABA_{B1}-^{-(orexin)} mice responded with

depolarization to BIC application (n=4) (Figure 3c). These findings indicate that GABA_A receptors

are tonically activated in orexin neurons of GABA_{B1}-/-(orexin) mice but not in wild-type mice. The

spontaneous excitatory postsynaptic currents (sEPSCs) of orexin neurons from GABA_{B1}-/-(orexin) and

control littermate mice were comparable (GABA_{B1}^{-/-(orexin)}: 5.1±0.73 Hz, n=4; control: 5.8±1.2 Hz, n=3;

p= 0.74). These results indicate that the inhibitory GABA_A input to orexin neurons is increased, while

excitatory glutamatergic input to orexin neurons remains unchanged in GABA_{B1}-/-(orexin) mice. This

mechanism might prevent offset of the resting membrane potential and firing frequency of orexin

neurons in $GABA_{B1}^{-/(orexin)}$ mice.

To further analyze the mechanisms that increase sIPSC frequency in orexin neurons lacking $GABA_B$ receptors, we recorded miniature IPSCs (mIPSCs). mIPSCs were isolated by adding

tetrodotoxin (TTX) (1 μ M) to the sIPSC recording solution. We found that the mean frequency and

peak currents of mIPSCs in orexin neurons of GABA_{B1}-/-(orexin) mice were comparable to that of control

mice (GABA_{B1}^{-/-(orexin)}: 1.1±0.29 Hz, 94.5±21.0 pA, n=5; control: 0.99±0.26 Hz, 104.5±11.2 pA, n=6;

p>0.05 by Student's t test). These results suggest that the increase of sIPSCs in GABA_{B1}-deleted

orexin neurons is due to an increase in the local GABAergic tone, rather than to an increase in

GABA_A receptors or the number of GABAergic synapses. Due to increase in GABA_A input, the

membrane resistance of orexin neurons in *GABA_{B1}*^{-/-(orexin)} mice was significantly decreased (control:

466 ± 29 MΩ, n=25; $GABA_{B1}^{-t-(orexin)}$: 364 ± 27 MΩ, n=12; p= 0.017, Student's *t* test) (Figure 3e).

Since the genetic deletion of the GABA_{B1} gene is restricted to orexin neurons (Figure 1), the

increase in sIPSP frequency in orexin neurons must be attributable to a dysregulation of these

neurons. Interestingly, we found that application of orexin A (1 µM) increased the frequency of

sIPSCs in wild-type orexin neurons (baseline: 1.6 ± 0.25 Hz; orexin A: 2.7 ± 0.33 Hz; washout: 1.5 ±

0.32 Hz; n= 5; p <0.05 by one-way ANOVA), suggesting that orexin-induced activation of local

GABAergic neurons is involved in the increase of inhibitory input to orexin neurons in GABA_{B1}-/-(orexin)

mice. We hypothesized that the activity of local GABAergic neurons expressing the orexin receptor

is increased in GABA_{B1}^{-/-(orexin)} mice due to increased orexin release onto these interneurons. To

evaluate this possibility, the orexin receptor antagonist SB334867 was used to block the orexin

receptor-1 (OX₁R). Preincubation with SB334867 (5 μM) reduced the frequency of sIPSCs in orexin

neurons of $GABA_{B1}^{--(\text{orexin})}$ mice (basal: 2.7 ± 0.43 Hz, n = 6; SB334867: 1.1 ± 0.30 Hz, n = 7; p=

0.012 by Student t test), but had no effect in control littermate mice $(1.1 \pm 0.36 \text{ Hz}, n = 4 \text{ vs } 1.0 \pm 1.0 \text{ s})$

0.13 Hz, n = 9, p= 0.769 by Student t test) (Fig, 3d). These results indicate that orexin activates local

GABAergic neurons via the OX1R resulting in an increase of the GABAergic synaptic input onto

orexin neurons, and that activity of these local circuits is increased in GABA_{B1}^{-/-(orexin)} mice.

Decreased Responsiveness of Orexin Neurons Lacking GABA_B Receptors to Excitatory and

Inhibitory Inputs

Although the basal membrane potential and firing frequency of orexin neurons in GABA_{B1}-^{(-(orexin)} mice

were comparable to that of wild-type mice due to the compensatory increase in GABAergic input, the

absence of GABA_B receptors caused abnormalities in these cells. We found that the effect of the

GABA_A agonist muscimol on orexin neuron activity was markedly attenuated in GABA_{B1}--(orexin) mice

(Figure 4a, b). In current clamp mode, the threshold for hyperpolarization of orexin neurons by

muscimol was 1.2 µM and 6 µM in littermate control slices and GABA_{B1}--(orexin) slices, respectively.

These findings indicate that the responses of orexin neurons to the GABA_A agonist muscimol are

decreased in slices from GABA_{B1}^{-/-(orexin)} mice. Tonic activation of GABA_A receptors might explain

why the exogenous application of the GABAA agonist muscimol had a less potent effect on orexin

neurons in GABA_{B1}-/-(orexin) mice since, under basal conditions, GABA_A receptors in these neurons are

already tonically activated by GABA (Figure 3c).

Next, we examined the effect of an excitatory neurotransmitter, glutamate, on the activity of

orexin neurons. The effects of glutamate were markedly attenuated in GABA_{B1}^{-/-(orexin)} mice (Figure

4c, d). These findings suggest a decrease in the membrane resistance of orexin neurons in

GABA_{B1}^{-/-(orexin)} mice (Figure 3e) due to excess GABA_AR activation by increased local GABAergic

neuron activity which results in decreased sensitivity to both excitatory and inhibitory inputs. This

decreased sensitivity might be due to the increase in membrane conductance (Figure 3e), which

caused shunting of excitatory input, although the resting membrane potential was comparable to

control.

GABA_{B1}^{-/-(orexin)} Mice Exhibit Severe Behavioral State Disruption

To examine the in vivo consequences of dysregulation of orexin neurons resulting from the absence

of GABA_B receptors, behavioral state patterns of GABA_{B1}-/-(orexin) mice and control littermate mice

were studied by simultaneous EEG/EMG recordings^{5,19,20}. Typical hypnograms (graphic

representations of sleep-waking states over time) of GABA_{B1}-/-(orexin) mice and control littermates

during the 24 hr dark and light periods are shown in Figure 5a and 5b. Although the overall amounts

of wakefulness, non-REM, and REM sleep were similar between the two strains (Figure 5c),

GABA_{B1}-/-(orexin) mice displayed severe fragmentation of sleep/wakefulness states indicated by

decreased awake, non-REM, and REM sleep episode durations and reduced REM latency (Figure

5d and Table 1). The fragmentation of sleep/wakefulness states in GABA_{B1}-/-(orexin) mice was more

severe than that previously described in orexin-knockout mice or even in orexin/ataxin-3 transgenic

mice in which orexin neurons are specifically ablated^{5,20}. However, neither the direct transitions from

an awake state to REM sleep nor the cataplexy-like behavioral arrests that are occasionally

observed in both orexin-deficient mice and orexin neuron-ablated mice were observed in

GABA_{B1}^{-/-(orexin)} mice^{5,20}. Interestingly, in contrast to the findings in orexin-deficient mice in which

fragmentation is only observed during the dark period,^{5,20} fragmentation of behavioral states in

GABA_{B1}^{-/-(orexin)} mice occurred during both the light and the dark periods (Figure 5 and Table 1).

Although the total sleep time of GABA_{B1}^{-/-(orexin)} mice tended to increase when compared to control

mice, this difference was not statistically significant (Figure 5 and Table 1). These changes along

with a decrease in REM sleep latency indicate increased pressure for entry into REM sleep in

 $GABA_{B1}^{-/-(orexin}$ mice.

Discussion

Orexin neurons are indispensable components of the regulatory mechanism that controls

sleep/wake states. We have previously studied the regulatory mechanisms of orexin neurons in

vitro^{7,8,21-24}. However, the physiological relevance of the regulatory mechanisms or inputs affecting

the activity of orexin neurons remains unknown. In this study, we addressed the importance of

GABA, the major inhibitory neurotransmitter in the mammalian central nervous system, because the

proper functioning of neurons is dependent upon the regulation of neural activity by GABA-releasing

neurons. Moreover, GABA has been implicated in the regulation of sleep. For instance, GABAA

receptor activation is well-known to induce sleep-promoting responses²⁵. Administration of the

GABA_B agonist baclofen (25 mg) before sleep in a clinical study also significantly prolonged total

sleep time and reduced the time spent awake after sleep onset²⁶. The GABA_B antagonist CGP

35348 increased the duration of both non-REM and REM sleep in aged rats compared to those in

saline-injected controls when injected during the night²⁷ and decreased non-REM sleep while

increasing the duration of waking and REM sleep when injected during the day²⁸. These results

suggest an important role for GABA_B receptors in the regulation of sleep/wakefulness states.

The present experiments showed that typical GABA_B responses are almost completely

eliminated in orexin neurons from GABA_{B1}-/-(orexin) mice (Figure 2). GABA_B agonist-induced

postsynaptic effects were also eliminated and the sensitivity of orexin neurons to both GABAA

receptor agonists and glutamate was decreased in GABA_{B1}-/-(orexin) mice (Figure 4). As shown in

Figure 3, we also found that inhibitory synaptic inputs to orexin neurons are increased in

GABA_{B1}-/-(orexin) mice. However, in the presence of TTX, mIPSC frequencies are comparable between

GABA_{B1}^{-/-(orexin)} and control orexin neurons (data not shown). These observations suggest that

spontaneous GABA release onto orexin neurons was not increased, but that activity-dependent

inhibitory signals from local GABAergic neurons onto orexin neurons were increased in slice

preparations from $GABA_{B1}^{--(orexin)}$ mice.

Because deletion of the GABA_BR was confined to orexin neurons (Figure 1), the increase

in GABAergic influence must be attributable to the abnormality of the orexin neurons. We suggest

that orexin neurons innervate local GABAergic neurons that, in turn, send inhibitory projections onto

the orexin neurons (Figure 6). In the parental GABA_{B1} floxed line, exons 7 and 8 of GABA_{B1} gene are

flanked by lox-P sites¹⁸. Therefore, both the GABA_{B1a} and GABA_{B1b} subtypes are deficient in the

orexin neurons of the GABA_{B1}^{-/-(orexin)} mice, which therefore lack functional GABA_B receptors

altogether. Presumably, in the GABA_{B1}-/-(orexin) mice, orexin release is increased due to the lack of

functional GABA_B receptors in the nerve terminal or the somatodendritic compartment of orexin

neurons, leading to excessive activation of local GABAergic neurons. Consistent with this hypothesis,

preincubation of GABA_{B1}-/-(orexin) slices with the OX₁R antagonist reduced the sIPSC frequency to a

level similar to that found in control slices (Figure 3d).

These alterations in the synaptic input of orexin neurons due to a lack of functional GABA_B receptors result in severe sleep/waking fragmentation in $GABA_{B7}^{-t-(orexin)}$ mice during both the light and dark periods (Figure 5 and Table 1), indicating that the GABA_B receptor in orexin neurons is indispensable for proper regulation of sleep/wake states. As to why $GABA_{B7}^{-t-(orexin)}$ mice showed robust fragmentation of sleep/wake behavior in both the dark and light periods, we have previously hypothesized that orexin neurons are appropriately regulated to maintain proper vigilance states according to the animals' environment¹. In $GABA_{B7}^{-t-(orexin)}$ mice, the effects of both GABA and

glutamate in orexin neurons were severely impaired. Therefore, orexin neurons in these mice are

unlikely to be appropriately and tightly regulated (Figure 4).

Orexin knockout mice and orexin neuron-deficient mice show behavioral instability and

sleep/wake fragmentation only during the dark (active) period^{5,20}. In contrast, transgenic mice with

constitutive overexpression of orexin show a fragmented sleep/wake phenotype only during the light

(rest) period. The activity of orexin neurons is high during the dark period²⁹; therefore, abnormality of

orexin^{-/-} mice during this period might be expected. On the other hand, since the activity of orexin

neurons is low or quiescent during the light period, the sleep/wake abnormality of

orexin-overexpressing mice becomes apparent during this period³⁰. However, GABA_{B1}-^{-/-(orexin)} mice

showed robust fragmentation of sleep/wake behavior during both the dark and light periods. In the

light (rest) period, orexin neurons might be inhibited by GABAergic influences from GABAergic

neurons in the preoptic area¹, which are likely important for stably silencing orexin neurons^{31,32}. In

GABA_{B1}^{-/-(orexin)} mice, both GABA_A- and GABA_B-mediated inhibition of orexin neurons was severely

impaired (Figures 2, 3, and 4). These defects may explain why these mice showed fragmented sleep

in the light period, because orexin neurons in GABA_{B1}^{-/-(orexin)} mice cannot be effectively inhibited by

GABA. On the other hand, during the dark (active) period, orexin neurons would be activated by

various excitatory inputs including glutamatergic influences¹. In GABA_{B1}-/-(orexin) mice, the effect of

glutamate on orexin neurons was also severely impaired (Figure 4); consequently, the activity of

orexin neurons is not appropriately regulated to maintain wakefulness according to various inputs

(Figure 6).

In GABA_{B1}^{-/-(orexin)} mice, we did not observe the cataplexy-like behavioral arrests or the direct

transitions from wakefulness to REM sleep that are occasionally seen in orexin-deficient animals.

This result is consistent with the observation that mice overexpressing orexin do not show cataplexy,

although these mice show fragmentation of sleep/wakefulness states during the light period³⁰.

Together, these results suggest that fine tuning of orexinergic tone may not be necessary for

inhibition of cataplexy and direct transition from wakefulness to REM sleep. On the other hand, the

present study showed that fine tuning of orexin neurons is crucial for stability of sleep/wakefulness

states and maintenance of normal sleep/wake architecture (Fig. 5d).

This study demonstrated the importance of GABA_B activity in a defined neuronal circuit and the

importance of orexin neuron GABABRs for maintenance of wakefulness and sleep state

consolidation. The phenotype of $GABA_{B1}^{-/-(orexin)}$ mice is characterized by impaired ability to maintain

any behavioral state, which is one of the primary symptoms of human narcolepsy. Therefore,

GABA_{B1}-/-(orexin) mice may be a useful model in which to study narcolepsy without cataplexy. Since the

partial GABA_B agonist GHB is used clinically to extend both sleep bouts and subsequent

wakefulness, thereby allowing narcoleptic humans to engage in longer periods of purposeful activity

during their waking hours, GABA_{B1}-/-(orexin) mice may also be a useful model in which to study the

therapeutic action of GHB. Impaired ability to maintain wakefulness and consolidate sleep is also

one of the hallmarks of sleep in the elderly. Given the widespread use of hypnotic medications that

target GABAergic signalling, it will be interesting to determine whether age-related defects in

GABAergic control of orexin neurons occur. Lastly, the orexin neurons have been proposed to be a

crucial component of a "flip-flop" switch controlling sleep and wakefulness²⁵. The orexin system is

hypothesized to be the stabilizer of the flip-flop switch¹. The phenotype of the GABA_{B1}-/-(orexin) mice

suggests that fine regulation of orexin neuronal activity is necessary for proper function of the flip-flop

switch.

Methods

Animal Usage

All experimental procedures involving animals were approved by the Animal Experiment and Use

Committee of University of Tsukuba and were in accordance with NIH guidelines.

Generation of Orexin/Cre Transgenic Mice

The transgenic construct was made by substituting the nlacZ gene (Sall-BamHI fragment) of the

orexin/nlacZ transgenic construct³³ with the Cre-recombinase cDNA and an internal ribosome entry

site with the eGFP (IRES-eGFP) gene (see supplementary information). The transgene was

linearized and microinjected into pronuclei of fertilized mouse eggs from the F1 of C57BL/6 x DBA1;

BDF1. Founder animals were bred with C57BL/6 mice to produce a stable orexin/Cre line.

Genotyping of orexin/Cre transgenic mice was performed by PCR of tail DNA. Human prepro-orexin

promoter sequences, Cre recombinase, and eGFP coding sequences were amplified with PCR

primer sets: human prepro-orexin genomic fragment, sense: GCAGCGGCCATTCCTTGG,

anti-sense: AAGTCGACGGTGTCTGGCGCTCAGGGTG; Cre recombinase, sense:

GGTTCGTTCACTCATGGAAAATAG, anti-sense: GGTATCTCTGACCAGAGTCATCCT; eGFP,

sense: GAAGGGCATCGACTTCAAGG, anti-sense: ACGAACTCCAGCAGGACCAT.

Breeding and Maintenance of Mouse Lines

mice (Jackson Laboratories) (Supplementary fig. 1).

Orexin/Cre mice were mated with $GABA_{B1}^{flox/flox}$ (BALB/cA) mice¹⁸ and a breeding colony for producing *orexin/Cre*, $GABA_{B1}^{flox/flox}$ ($GABA_{B1}^{-/-(orexin)}$; BALB/cA: C57BL/6: DBA1 mixed background) was maintained by mating $GABA_{B1}^{flox/flox}$ with *orexin/Cre*, $GABA_{B1}^{flox/+}$ mice. To detect Cre recombinase expression, we mated *orexin/Cre* Tg mice with 129-*Gt(ROSA)26Sor^(EGFP)/J* reporter

We produced mice with selective deletion of the $GABA_{B1}$ gene in orexin neurons by crossing

GABA_{B1} flox/flox and orexin/Cre Tg mice. The genetic background of the mice used in this study was a

mixture of BALB/c, C57BL/6, and DBA1 (75% : 21.875% : 3.125%). These mice with either a

C57BL/6 background or a C57BL/6 and DBA1 mixed background showed similar sleep/wakefulness

behavior, consistent with previous studies^{34,35}. The total daily duration of non-REM sleep did not

significantly differ between strains, even though the BALB/c strain has been reported to exhibit a

shorter period of time in non-REM sleep during the day than the night³⁶. These similarities suggest

that differences in genetic background have minimal effects on the results of our study. To further

minimize the effect of genetic background, all experiments were performed with littermates as

controls. We found that wild type mice, orexin/Cre Tg mice, GABA_{B1}^{flox/+}, orexin/Cre Tg mice and

GABA_{B1} flox/flox (orexin/Cre-negative) mice all show the same phenotype regarding sleep/wakefulness

states (data not shown). In this study, GABA_{B1} flox/flox, orexin/Cre Tg mice were used as GABA_{B1}

spatially-restricted KO mice, while GABA_{B1}^{-/-(orexin)} mice and their GABA_{B1}^{flox/flox}, orexin/Cre-negative

littermates were used as controls unless otherwise stated.

For electrophysiological analysis, $GABA_{B1}^{-/-(orexin)}$ mice were mated with *orexin/eGFP* transgenic mice (C57BL/6 background) to prepare $GABA_{B1}^{-/-(orexin)}$ mice with expression of eGFP as a marker of orexin neurons¹⁹.

Histological Analysis

Mouse brains were fixed and prepared as previously described³⁷. Mice were anesthetized by

intraperitoneal injection of sodium pentobarbital and perfused via the heart with phosphate-buffered

saline (PBS), followed by 0.1 M phosphate buffer containing 4% paraformaldehyde. The whole brain

was postfixed for 2 hr in 4% paraformaldehyde in PBS. Sections were washed with 0.3% Triton

X-100 in PBS and incubated with 1% bovine serum albumin in PBS for 1 hr, and then incubated with

primary antibodies in the same solution for 1 hr at room temperature. Staining was performed with

standard procedures using rabbit or guinea pig anti-orexin antisera³⁷, mouse anti-Cre antibody

(Nacalai), or guinea pig anti-GABA_{B1} antibody (Chemicon) and Alexa 488 or 594-conjugated

secondary antibodies (Invitrogen).

EEG/EMG Recording

Male GABA_{B1}^{-/-(orexin)} mice (n=10) and their weight-matched male control littermates (GABA_{B1}^{flox/+},

orexin/Cre Tg mice, n=5; or GABA_{B1}^{flox/flox} (orexin/Cre-negative) mice, n=6) were implanted with

electrodes at 12 weeks of age to record simultaneous EEG/EMG, as described previously⁵. Animals

were allowed to recover and habituate for 2 weeks under a constant 12 hr light/dark cycle at 25°C

with free access to food and water. Continuous EEG/EMG traces were recorded with ad libitum

feeding for the first 48 hr (baseline). Traces were captured and digitized in 20 s epochs. Each of two

investigators, blinded to genotype, scored and categorized all epochs as wakefulness, REM sleep,

or non-REM sleep according to standard criteria of rodent sleep. REM latency was determined as

the time between the onset of sleep and the first REM sleep period. Inter-REM interval was

calculated as the duration between successive REM sleep episodes. Data were analyzed by

ANOVA for repeated measurements to detect interactions between genotype and vigilance state parameters.

Electrophysiological Studies

Male and female GABA_{B1}^{-/-(orexin)} (GABA_{B1}^{flox/flox}, orexin/Cre Tg), control (GABA_{B1}^{flox/+}; orexin/Cre Tg or

GABA_{B1}^{flox/flox}, orexin/Cre negative), and orexin/eGFP mice, 2-5 weeks old, were used for the

experiments. The brain was cut coronally into 300-µm slices with a microtome (Leica) in

Ringer-sucrose buffer bubbled with 95% O2/5% CO2 gas. Slices containing the LHA were

transferred to an incubation chamber filled with a physiological solution containing the following (in

mM): 140 NaCl, 2 KCl, 1 CaCl₂, 1 MgCl₂, 10 HEPES, and 10 glucose, pH 7.4, at room temperature

(24-26°C) for at least for 1 hr. For electrophysiological recording, the slices were kept at a controlled

temperature of 34°C and were superfused with a physiological solution that was warmed by an in-line

heater (Warner Instruments) to 34°C. A fluorescence microscope equipped with an infrared camera

(Hamamatsu Photonics) for infrared differential interference contrast imaging and a charge-coupled

device camera (Olympus Optical) was used for fluorescent imaging. For whole cell patch-clamp

recording, pipettes were filled with an internal solution, HEPES-buffered potassium chloride (KCI) or

potassium methanesulfonate (KMeSO₄) solution, as previously described⁹. Pipette resistance was

5-10 M Ω . The series resistance during recording was 10-40 M Ω and was not compensated. The

liquid junction potential of the patch pipette solution and perfused HEPES solution was estimated to

be 3.9 mV and was applied to the data. The membrane patch was then ruptured by suction, and

membrane current and potential were monitored using an Axopatch 200B patch-clamp amplifier

(Axon Instruments). Data were recorded on a computer through a Digidata 1322A analog-to-digital

converter using pClamp 10.0 software (Axon Instruments). sEPSCs were recorded using KCl

internal solution supplemented with the sodium channel blocker QX-314 (1 mM) to inhibit action

potentials in the neuron, and bicuculline (BIC; 20 µM) and picrotoxin (PTX; 100 µM) were added to

the physiological HEPES solution to block GABA_A receptor-mediated neurotransmission. sIPSCs

were recorded using the same pipette solution but with addition of

6-cyano-7nitroquinoxaline-2,3-dione (CNQX, 20 µM) and DL-2-amino-5-phosphono-pentanoic acid

(AP-5, 50 µM) to the bath solution to block AMPA and NMDA receptor-mediated neurotransmission.

mIPSCs were recorded in the presence of 1 µM TTX, 20 µM CNQX and 50 µM AP-5. Frequencies

and amplitudes of spontaneous and miniature synaptic events were measured using the Mini

Analysis Program version 6.0 (Synaptosoft) from recordings before, during and after washout of the

drug. Only those events with amplitudes > 10 pA were used. Electrophysiological traces were

processed for presentation using Origin 7.5 (Origin Lab Corporation).

Drugs

The drugs used were glutamate, GABA, muscimol, baclofen, BIC, PTX, CNQX, 5-HT, and AP5

(Sigma), TTX (Wako), CGP54626 and SB334867 (Tocris), and CCK, orexin A and orexin B (Peptide

Institute). Drugs were dissolved in DMSO or the buffers suggested by the suppliers and were diluted

with bath HEPES buffer.

Statistical Analysis

Data are presented as mean±SEM and were analyzed by one-way or repeated-measurements

ANOVA followed by post hoc analysis of significance by Scheffé's F test or Fisher's Protected Least

Significant Difference test using the GraphPad Prism version 4 software package (GraphPad

Software).

References

- Sakurai, T. The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness. *Nat Rev Neurosci* 8, 171-81. (2007).
- Lin, L. et al. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. *Cell* 98, 365-376 (1999).
- 3. Peyron, C. et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. *Nat. Med.* **9**, 991-997 (2000).
- 4. Thannickal, T.C. et al. Reduced number of hypocretin neurons in human narcolepsy. *Neuron* 27, 469-474 (2000).
- 5. Chemelli, R.M. et al. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. *Cell* **98**, 437-451 (1999).
- 6. Yoshida, K., McCormack, S., Espana, R.A., Crocker, A. & Scammell, T.E. Afferents to the orexin neurons of the rat brain. *J Comp Neurol.* **494**, 845-861 (2006).
- Li, Y., Gao, X.B., Sakurai, T. & van den Pol, A.N. Hypocretin/Orexin excites hypocretin neurons via a local glutamate neuron-A potential mechanism for orchestrating the hypothalamic arousal system. *Neuron* 36, 1169-1181 (2002).
- Yamanaka, A., Muraki, Y., Tsujino, N., Goto, K. & Sakurai, T. Regulation of orexin neurons by the monoaminergic and cholinergic systems. *Biochem Biophys Res Commun.* 303, 120-129 (2003).
- Xie, X. et al. GABA(B) receptor-mediated modulation of hypocretin/orexin neurones in mouse hypothalamus. *J Physiol.* 574, 399-414 (2006).
- Marshall, F.H., Jones, K.A., Kaupmann, K. & Bettler, B. GABAB receptors the first 7TM heterodimers. *Trends Pharmacol Sci* 20, 396-9 (1999).
- Mohler, H. & Fritschy, J.M. GABAB receptors make it to the top--as dimers. *Trends Pharmacol Sci* 20, 87-9 (1999).
- Bowery, N.G. et al. International Union of Pharmacology. XXXIII. Mammalian gamma-aminobutyric acid(B) receptors: structure and function. *Pharmacol Rev.* 54, 247-264

(2002).

- 13. Bettler, B., Kaupmann, K., Mosbacher, J. & Gassmann, M. Molecular structure and physiological functions of GABA(B) receptors. *Physiol Rev.* **84**, 835-867 (2004).
- Vigot, R. et al. Differential compartmentalization and distinct functions of GABAB receptor variants. *Neuron* 50, 589-601 (2006).
- Shaban, H. et al. Generalization of amygdala LTP and conditioned fear in the absence of presynaptic inhibition. *Nat Neurosci* 9, 1028-35 (2006).
- Lingenhoehl, K. et al. Gamma-hydroxybutyrate is a weak agonist at recombinant GABA(B) receptors. *Neuropharmacology* 38, 1667-1673.
- Schuler, V. et al. Epilepsy, hyperalgesia, impaired memory, and loss of pre- and postsynapticGABA(B) responses in mice lacking GABA(B(1)). *Neuron* **31**, 47-58. (2001).
- 18. Haller, C. et al. Floxed allele for conditional inactivation of the GABAB(1) gene. *Genesis* 40, 125-30 (2004).
- Yamanaka, A. et al. Hypothalamic orexin neurons regulate arousal according to energy balance in mice. *Neuron* 38, 701-713 (2003).
- 20. Hara, J. et al. Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity. *Neuron* **30**, 345-354 (2001).
- Muraki, Y. et al. Serotonergic regulation of the orexin/hypocretin neurons through the
 5-HT1A receptor. *J. Neurosci.* 24, 7159-7166 (2004).
- Sakurai, T. Reverse pharmacology of orexin: from an orphan GPCR to integrative physiology. *Regul Pept* 126, 3-10 (2005).
- Sakurai, T. et al. Input of Orexin/Hypocretin Neurons Revealed by a Genetically Encoded Tracer in Mice. *Neuron* 46, 297-308 (2005).
- 24. Yamanaka, A. et al. Orexin neurons are directly and indirectly regulated by catecholamines in a complex manner *J. Neurophysiol.* **96**, 284-298 (2006).
- Saper, C.B., Scammell, T.E. & Lu, J. Hypothalamic regulation of sleep and circadian rhythms. *Nature* 437, 1257-63 (2005).

- Finnimore, A.J., Roebuck, M., Sajkov, D. & McEvoy, R.D. The effects of the GABA agonist, baclofen, on sleep and breathing. *Eur Respir J* 8, 230-4. (1995).
- Puigcerver, A., van Luijtelaar, E.L., Drinkenburg, W.H. & Coenen, A.L. Effects of the GABAB antagonist CGP 35348 on sleep-wake states, behaviour, and spike-wave discharges in old rats. *Brain Res Bull* 40, 157-62. (1996).
- 28. Gauthier, P., Arnaud, C., Gandolfo, G. & Gottesmann, C. Influence of a GABA(B) receptor antagonist on the sleep-waking cycle in the rat. *Brain Res* **773**, 8-14. (1997).
- Estabrooke, I.V. et al. Fos expression in orexin neurons varies with behavioral state. J Neurosci. 21, 1656-1662 (2001).
- Mieda, M. et al. Orexin peptides prevent cataplexy and improve wakefulness in an orexin neuron-ablated model of narcolepsy in mice. *Proc Natl Acad Sci U S A*. 101, 4649-4654 (2004).
- 31. Alam, M.N. et al. GABA-mediated control of hypocretin- but not melanin-concentrating hormone-immunoreactive neurones during sleep in rats. *J Physiol.* **563**, 569-582 (2005).
- 32. Suntsova, N. et al. The median preoptic nucleus reciprocally modulates activity of arousal-related and sleep-related neurons in th perifornical lateral hypothalamus. *J Neurosci.* 27, 1616-1630 (2007).
- 33. Sakurai, T. et al. Structure and function of human prepro-orexin gene. *J Biol Chem* 274, 17771-17776 (1999).
- 34. Maret, S. et al. Retinoic acid signaling affects cortical synchrony during sleep. *Science* 310, 111-3. (2005).
- 35. Tafti, M. & Franken, P. Genetic dissection of sleep. J Appl Physiol 92, 1339-47. (2002).
- Toth, L.A. Strain differences in the somnogenic effects of interferon inducers in mice. J Interferon Cytokine Res 16, 1065-72. (1996).
- 37. Nambu, T. et al. Distribution of orexin neurons in the adult rat brain. *Brain Res.* 827, 243-260 (1999).
- 38. Mao, X., Fujiwara, Y., Chapdelaine, A., Yang, H. & Orkin, S.H. Activation of EGFP

expression by Cre-mediated excision in a new ROSA26 reporter mouse strain. Blood 97,

324-6 (2001).

Figure legends

Figure 1. Selective Loss of GABA_B Receptors in Orexin Neurons in GABA_{B1}^{-/-(orexin)} Mice.

GABA_{B1}^{-/-(orexin)} (GABA_{B1}^{flox/flox}, orexin/Cre Tg) mice showed loss of GABA_{B1} receptor gene expression

in orexin neurons. Matched brain sections from GABA_{B1}-/-(orexin) and wild-type littermate mice were

double-stained with anti-orexin and anti-GABA_{B1} receptor serum. Left: orexin-like immunoreactive

neurons in LHA; middle: GABA_{B1} receptor-like immunoreactive neurons; right: merged image.

Lower panels are high-power views of the areas surrounded by the white rectangles in the

corresponding upper panels.

Figure 2. Lack of Functional GABA_B Receptors in Orexin Neurons of GABA_{B1}-/-(orexin) Mice. (a)

Effects of GABA (0.6 mM), muscimol (30 μ M), baclofen (100 μ M), and 5-HT (10 μ M) in orexin

neurons in control mice during current-clamp recording (n=4-8). Drugs were applied during the

periods indicated by bars. (b) Effects of GABA (0.6 mM), muscimol (30 μ M), baclofen (100 μ M), and

5-HT (10 μ M) in orexin neurons from *GABA*_{B1}^{-/-(orexin)} mice (n=4-12).

Figure 3. Alteration of Spontaneous Synaptic Input to Orexin Neurons of GABA_{B1}^{-/-(orexin)} Mice.

(a) sIPSC recordings from brain slices of littermate (control) and GABA_{B1}-/-(orexin) mice. Basal (upper),

baclofen (100 μM) application (middle), and after drug washout (lower). IPSCs were recorded in the

presence of AP-5 (50 μ M) and CNQX (20 μ M). (b) Effects of baclofen on sIPSC frequencies in

control (n=13) and GABA_{B1}-/-(orexin) (n=9) mice recorded for at least 3 minutes. (c) In current-clamp

recording mode, the GABA_A receptor antagonist BIC (25 µM) was applied to orexin neurons of

control (upper, n=4) and $GABA_{B1}^{--(orexin)}$ (lower, n=4) mice. (d) Basal (control, n = 4, cKO, n = 6) and

mean effect of pre-incubation with OX₁R antagonist, SB334867 (5 μM; control n = 9, cKO, n = 7), on

sIPSC frequency in $GABA_{B1}^{-/(\text{orexin})}$ (cKO) mice. Data shown are mean ± SE. *, P < 0.05. Data were

analyzed by one way ANOVA or Student's t test. (e) Membrane potential of orexin neurons in control

(n=25) vs. GABA_{B1}-/-(orexin) mice (n=12) in response to a series of 100 msec current steps (in 20 pA

increments, -200 to 80 pA) from resting potential (-60mV). Data shown are mean±SE. *, P < 0.05.

Data were analyzed by one way ANOVA or Student's t test.

Figure 4. Action of GABA_A Agonist and Glutamate on Orexin Neurons of GABA_{B1}-/-(orexin) Mice.

(a) In voltage clamp mode with V_m held at -60 mV, muscimol (10 μ M) induced an outward current in

orexin neurons of control (upper) and GABA_{B1}-/-(orexin)</sub> (lower) mice. The effect of muscimol was

smaller in GABA_{B1}-/-(orexin) mice. (b) Dose effects of muscimol on orexin neurons of control (n=6-10)

vs $GABA_{B1}^{-(\text{orexin})}$ mice (n=9-12). (c) In voltage clamp mode with with V_m held at -60 mV, glutamate

(100 μ M) induced an inward current in orexin neurons of control (upper) and $GABA_{B1}^{-/-(orexin)}$ (lower)

mice. The effect of glutamate was smaller in $GABA_{B1}^{-/-(orexin)}$ mice. (d) Dose effects of glutamate on

orexin neurons of control (n=5-13) vs GABA_{B1}-^{-(orexin)} mice (n=3-8). Representative recordings (a and

c) and summary data are shown as mean±SE (b and d).

Figure 5. Severe Fragmentation of Sleep Stages in GABA_{B1}-/-(orexin) Mice. Representative 24 hr

hypnograms for a GABA_{B1}-/-(orexin) mouse (a) and a control littermate (b). W, wakefulness; NR,

non-REM sleep; R, REM sleep. Note the severe sleep/waking fragmentation, reduced wakefulness

duration, and reduced REM latency in the GABA_{B1}-/-(orexin) mouse relative to control. Hourly amounts

(c) and average episode duration (d) of awake, non-REM, and REM sleep states (mean±SE)

plotted over 24 hr for control littermate (n=11) and GABA_{B1}^{-/-(orexin)} mice (n=10). Data for the dark

and light phases are displayed on light gray and white backgrounds, respectively. *P < 0.05 by

Student's t test.

Figure 6. Proposed Model in $GABA_{B1}^{-/-(orexin)}$ Mice Displaying Sleep/Wakefulness Fragmentation. GABA_A input is increased by compensatory mechanisms, resulting in increased membrane conductance of orexin neurons in $GABA_{B1}^{-/-(orexin)}$ mice. Therefore, orexin neurons in $GABA_{B1}^{-/-(orexin)}$ mice show decreased responses to both excitatory and inhibitory input. In vivo,

responses of orexin neurons in $GABA_{B1}^{-/(orexin)}$ mice to wake-active excitatory input or sleep-active

inhibitory input are inappropriate, resulting in severe instability of sleep/wakefulness states.

Supplementary information

Generation of Transgenic Mice in which Orexin Neurons Specifically Express Cre

Recombinase

To achieve orexin neuron-specific Cre expression, a transgene was constructed with the 3.2 kb

fragment of the 5'-upstream region of the human prepro-orexin gene as a promoter ³³, which was

ligated to the Cre recombinase cDNA fused to an IRES-eGFP construct (Supplementary figure 1a).

Using this transgene, several transgenic mouse lines, orexin/Cre transgenic mice, were established.

To confirm Cre expression, immunohistochemical staining was carried out using an anti-Cre

antibody (Nacalai). Cre-immunoreactivity (ir) was observed in most (~80%) of the orexin-containing

neurons (Supplementary figure 1b). Expression of eGFP could not be detected by

immunohistochemical or direct GFP fluorescence analysis, suggesting that the IRES-eGFP system

was non-functional in orexin neurons. To examine if functional Cre protein is expressed in orexin

neurons, orexin-Cre mice were crossed with 129-Gt(ROSA)26Sor^(EGFP)/J reporter mice³⁸. This

confirmed that Cre activity expressed as eGFP-fluorescence was restricted to orexin neurons in the

LHA (Supplementary figure 1c). Similar results were obtained using ROSA-LacZ reporter mice and

LacZ staining (data not shown). Extensive examination throughout the brain failed to identify ectopic

GFP expression other than that in orexin neurons (data not shown). These observations suggest

that functional Cre recombinase is exclusively expressed in orexin neurons in orexin/Cre transgenic

mice.

Legend for Supplementary figure 1 Transgenic Mice Specifically Expressing Cre Recombinase Only in Orexin Neurons. (a) Structure of the orexin/Cre (IRES-eGFP) transgene, consisting of human prepro-orexin promoter, Cre recombinase (Cre) cDNA, IRES-eGFP cDNA, and murine protamine-1 gene fragment (mPrm1 polyA). (b) Specific expression of Cre recombinase by orexin-containing neurons in the lateral hypothalamic area (LHA) of orexin/Cre transgenic mice is shown by immunofluorescence. Left, Cre recombinase-like immunoreactivity (Alexa 594, red); middle, orexin-like immunoreactivity (Alexa 488, green); right, merged images. (c) Expression of Cre recombinase was monitored by crossing ROSA-eGFP reporter mice. Left, orexin-like immunoreactivity (red); middle, eGFP fluorescence (green); right, merged images.


REM			Non-REM		Awake	
Light period	$GABA_{B1}^{-/-(orexin)}$	Control	$GABA_{B1}^{-/-(orexin)}$	Control	$GABA_{B1}^{-/-(\text{orexin})}$	Control
(8:00~20:00)	(n=10)	(n=11)	(n=10)	(n=11)	(n=10)	(n=11)
Total time (min)	61.8±3.7	54.6±5.1	402.2±11.6	384.0±16.2	254.1±11.7	280.1±18.5
Duration (sec)	67.3±3.5	78.8±3.2	240.6±24.0**	369.4±27.0	208.0±22.5**	498.2±71.5
Episode counts	57.0±5.1*	42.1±3.9	108.5±11.8**	65.5±3.6	79.9±7.9**	40.0±4.9
REM latency (sec)	295.0±30.5*	410.3±24.8				
Inter-REM interval (sec)	759.6±79.9	1060.1±103.8				

Table 1. Vigilance State Parameters Recorded from GABA_{B1}^{-/-(orexin)} and Control Mice

	REM		Non-REM		Awake	
Dark period	GABA _{B1} -/-(orexin)	Control	GABA _{B1} -/-(orexin)	Control	GABA _{B1} -/-(orexin)	Control
(20:00~8:00)	(n=10)	(n=11)	(n=10)	(n=11)	(n=10)	(n=11)
Total time	36.7±2.7	32.0±3.0	282.4±12.7	286.9±15.3	400.2±15.0	405.4±20.2
(min)						
Duration (sec)	69.1±3.2**	84.2±3.2	231.6±22.2**	392.4±40.4	387.1±65.7*	883.7±127.4
Episode	32.9±3.3*	23.5±2.5	82.8±11.8**	46.7±3.6	68.5±12.0**	32.4±3.9
counts						
REM latency	285.6±28.3*	503.2±53.6				
(sec)						
Inter-REM	1356.9±204.2	2091±417.5				
interval (sec)						

Total time spent in each state (min, mean \pm SEM), episode duration (sec \pm SEM), REM latency, and interval between successive REM sleep episodes (min, mean \pm SEM) over 24 hr are itemized separately for the light and dark periods. Significant differences (*P<0.05,**P<0.01; one-way ANOVA and *post hoc* Scheffé's F test) between *GABA_{B1}*^{-/-(orexin)} and control (*GABA_{B1}*^{flox/flox}, *orexin/Cre* negative) mice are indicated with asterisks.

Figure 1. Matsuki et al.,




Orexin-ir

GABAB1-/-(ore Within Precedings : hd:10101/hpre 2007.1195.1 : Posted Cap 2007.rol


GABAB1-ir

Merge



GABAB1-/-(orexin)

Figure 3. Matsuki et al.,



Control GABAB1-/-(orexin)


10-5


Control GABAB1-(-(orexin)

10-4

10-4

10-3





Control

GABAB1-/-(orexin)

